伊布利特治疗阵发性房颤的疗效及安全性

目的：观察新型Ⅲ类抗心律失常药物伊布利特转复心房纤颤的疗效。方法：选择32例房颤患者，随机分为两组：伊布利特组（18例），伊布利特1mg，于15min内静注，如无效30min后再给予1mg静注；胺碘酮组（14例），胺碘酮150mg，于15min内静注，如无效30min后再给予150mg静注。观察两组房颤转复情况及时间。结果：伊布利特组90min内转复房颤率明显高于胺碘酮组（77．8％比28．6％），4h内转复房颤率亦明显高于胺碘酮组（100％比71．4％），P〈0．01。结论：伊布利特是一种转复房颤的快速、安全、有效的药物。

Clinical effects and safety of ibutilide in patients with paroxysmal atrial fibrillation

Objective:To observe effect of ibutilide,a new Ⅲ antiarrhythmic drug,for atrial fibrillation(AF)cardioversion.Methods:A total of 32 AF patients were randomly divided into ibutilide group(n=18,received ibutilide 1mg intravenous within 15min,another 1mg was given intravenously after 30min if it was invalid) and amiodarone group(n=14,received amiodarone 150mg intravenous within 15min,another 150mg was given intravenously after 30min if it was invalid).Cardioversion condition and time were observed in two groups.Results:Cardioversion rate of AF within 90min in ibutilide group was significantly higher than that of amiodarone group(77.8% vs.28.6%),that within 4h was also significantly higher than that of amiodarone group(100% vs.71.4%),P<0.01 both.Conclusion:Ibutilide is a drug for safe and effective cardioversion of atrial fibrillation.